Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.
USANA Health Sciences (USNA) is back in focus after Q2 2026 results showed sales of $223.27 million, a swing to a net loss, lowered full year guidance, and a $29 million goodwill impairment charge.
See our latest analysis for USANA Health Sciences.
The Q2 2026 results and lowered guidance have coincided with sharp selling in USANA Health Sciences, with the share price down 34.2% over the past day and the 1-year total shareholder return down 48.29%, suggesting momentum has been weakening rather than building.
If USANA Health Sciences' latest move has you reassessing your watchlist, it could be a useful moment to scan other health focused opportunities through our screener of 42 healthcare AI stocks
After USANA Health Sciences' sharp drop and new loss outlook, the question now is whether most of the pain is already reflected in the share price or if the recent move has simply cut into future upside.
Price-to-Sales of 0.3x for USANA Health Sciences: Is it justified?
On Simply Wall St's numbers, USANA Health Sciences trades on a P/S of roughly 0.3x, which flags the stock as screened good value compared with both peers and the wider Personal Products industry.
The P/S ratio compares the company's market value with its revenue and is often used when earnings are weak or volatile, as is the case with USANA Health Sciences which is currently loss making. At around 0.3x sales, the market is pricing each $1 of revenue at a clear discount to the sector, while our fair P/S estimate sits closer to 0.8x.
Against U.S. Personal Products peers, where the average P/S is 2.4x and the industry average is 0.8x, USANA Health Sciences sits at a much lower level. If the company's revenue profile and cash generation track closer to those industry norms over time, there is room for the valuation multiple to move toward that higher fair ratio level.
Explore the SWS fair ratio for USANA Health Sciences
Result: Price-to-Sales of 0.3x (UNDERVALUED)
However, USANA Health Sciences still faces pressure from the recent net loss and goodwill impairment, and any further guidance cuts could quickly reset investor expectations again.
Find out about the key risks to this USANA Health Sciences narrative.
Another view on USANA Health Sciences using the SWS DCF model
The earlier P/S work suggested USANA Health Sciences screens as good value. The SWS DCF model points in the same direction, with an estimated future cash flow value of $43.64 per share versus the current $14.99 price. That implies a large discount, but also raises a question about how realistic those cash flow assumptions are.
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day ( check out USANA Health Sciences for example ). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks . If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Given the mix of concern and optimism around USANA Health Sciences right now, it makes sense to move quickly and review the underlying data yourself. Before making any decision, take a balanced look at the company's 3 key rewards and 2 important warning signs
Looking for more investment ideas beyond USANA Health Sciences?
If this update on USANA Health Sciences has sharpened your focus, now is a smart time to widen your watchlist with a few targeted stock ideas.
-
Target potential mispricing by checking companies that currently screen as good value on our list of 51 high quality undervalued stocks .
-
Prioritize resilience by reviewing companies that feature in our 79 resilient stocks with low risk scores for steadier balance sheets and lower risk scores.
-
Get ahead of the crowd by scanning the screener containing 17 high quality undiscovered gems that combine strong fundamentals with lower market attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include USNA .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
